Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × magrolimab × Lymphoid × Clear all
NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Stanford University

Phase 2 Active not recruiting
8 enrolled
Lymphoid

Hodgkin Disease

NCT05929716 2023-11-13

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡